Genprex, Inc. (GNPX) has announced its intention to establish a wholly-owned subsidiary dedicated exclusively to its diabetes clinical development program and gene therapy assets. This new entity will focus on the progression and commercialization of GPX-002, a gene therapy candidate targeted at treating both Type 1 and Type 2 diabetes.
GPX-002, licensed from the University of Pittsburgh, employs an AAV vector that delivers the Pdx1 and MafA genes directly into the pancreatic duct.
Should the spin-out proceed as planned, this new subsidiary will concentrate solely on GPX-002, while Genprex will continue its efforts in oncology and sustain its current oncology projects.
The spin-out is expected to be completed by the end of 2024, subject to financing and approval from the board.
